LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy.
Ipsen, Genfit unveil additional PhIII data for rare liver disease drug, further boosting regulatory ambition
Ipsen and Genfit revealed on Monday that their primary biliary cholangitis (PBC) drug candidate has met additional endpoints in a registrational trial, adding fuel to